Carnegie has undertaken stabilisation measures in Devyser Diagnostics AB (publ)’s shares corresponding to c. 2.3 percent of the Over-allotment Option in total
Stockholm, 29 December, 2021 Carnegie Investment Bank AB (publ) (“Carnegie”) has undertaken stabilisation measures in Devyser Diagnostics AB (publ)’s (“Devyser” or the “Company”) shares on Nasdaq First North Premier Growth Market (“First North”). As announced on 1 December 2021 in connection with the listing of the Company's shares on First North and the offering of shares made in connection thereto (the “Offering”), Carnegie may, as Sole Global Coordinator and Sole Bookrunner, carry out transactions aimed at supporting the market price of the Company’s share at levels above those